Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H12ClNO2 |
Molecular Weight | 273.714 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC2=C(C=C1)C3=C(N2)C=CC(Cl)=C3
InChI
InChIKey=PUXBGTOOZJQSKH-UHFFFAOYSA-N
InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
Molecular Formula | C15H12ClNO2 |
Molecular Weight | 273.714 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Carprofen is an anti-inflammatory drug developed in Japan by Nippon Roche Research Center. Carprofen, as many NSAIDs, selectively inhibits COX-2 and was shown to suppress inflammation in vitro, using osteoarthritis models. The drug was approved by FDA for human use under the name Ridamyl, however, now it is sold only for veterinary purposes and prescribed for the treatment of postoperative pain and the relief of pain and inflammation associated with osteoarthritis in dogs.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/304433
Curator's Comment: The full version can be found here: https://www.jstage.jst.go.jp/article/fpj1944/73/7/73_7_757/_pdf
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4033 |
0.102 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | RIMADYL Approved UseRimadyl is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. Launch Date1996 |
|||
Primary | RIMADYL Approved UseRimadyl is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
52.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
57.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3886707 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CARPROFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Sample Use Guides
The recommended dosage for oral administration to dogs is 2 mg/lb (4.4 mg/kg) of body weight daily.
The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb (2.2 mg/kg) twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26130858
Canine chondrocytes isolated from normal canine articular cartilage were used to create an in vitro model of osteoarthritis. Cells were incubated at 37C in a 5% CO2 atmosphere for 72 h and then treated with 500 uL of the pro-inflammatory cytokine, interleukin-1b (IL-1b) (10 ng/mL in serum-free medium) to induce inflammatory conditions and incubated at 37C in 5% CO2 atmosphere for 2 h. Carprofen was added to the cells at concentration from 0.1 to 250 ug/mL.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:18:28 GMT 2023
by
admin
on
Sat Dec 16 17:18:28 GMT 2023
|
Record UNII |
FFL0D546HO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.304
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
||
|
WHO-VATC |
QM01AE91
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
||
|
CFR |
21 CFR 522.304
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C65290
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
DB00821
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
3980
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
2581
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
518
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
53716-49-7
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
m3132
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
20343
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
258-712-4
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
FFL0D546HO
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
C007005
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
1096699
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
364453
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
SUB06144MIG
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
100000081327
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
FFL0D546HO
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
297935
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
7141
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1316
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
CARPROFEN
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY | |||
|
DTXSID1045871
Created by
admin on Sat Dec 16 17:18:28 GMT 2023 , Edited by admin on Sat Dec 16 17:18:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |